Orcet-M Syrup is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated for the management of allergic conditions such as allergic rhinitis and asthma. Levocetirizine is a potent, selective second-generation antihistamine that competitively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea associated with allergic responses. Montelukast is a leukotriene receptor antagonist that blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene-mediated bronchoconstriction, inflammation, and mucus production, which are key contributors to asthma and allergic rhinitis pathophysiology. The synergistic action of these two agents provides comprehensive relief from allergic symptoms and helps in controlling asthma exacerbations. Orcet-M Syrup is indicated for pediatric and adult patients requiring combined antihistaminic and leukotriene receptor antagonist therapy. It is generally well tolerated, with a favorable safety profile; common adverse effects may include headache, somnolence, and gastrointestinal disturbances. Dosage and duration should be as prescribed by a healthcare professional, considering the patient’s age, severity of symptoms, and clinical response. This combination therapy offers an effective approach to managing allergic diseases by targeting multiple pathways involved in the allergic cascade.